Better late than early: FDG-PET imaging in metastatic renal cell carcinoma.

Published

Journal Article

Sunitinib treatment benefits patients with metastatic renal cell carcinoma (mRCC), but response duration can vary widely and resistance is not predicted by standard measures. [¹⁸F]fluoro-2-deoxy-2-D-glucose positron emission tomography (FDG-PET) uptake is variable in mRCC, but changes in FDG-PET uptake may be useful in monitoring disease progression. Further work is needed to personalize treatment for patients with mRCC.

Full Text

Duke Authors

Cited Authors

  • Harrison, MR; George, DJ

Published Date

  • September 15, 2011

Published In

Volume / Issue

  • 17 / 18

Start / End Page

  • 5841 - 5843

PubMed ID

  • 21926167

Pubmed Central ID

  • 21926167

International Standard Serial Number (ISSN)

  • 1078-0432

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-11-1768

Language

  • eng

Conference Location

  • United States